OR
Cardiology - Clinical Cardiology
This conference update reviews five late-breaking clinical trials presented at ESC Congress 2026, highlighting new evidence with potential implications for contemporary cardiovascular practice. The update covers primary prevention with atorvastatin in older adults, factor XIa inhibition after acute coronary syndrome, aficamten in nonobstructive hypertrophic cardiomyopathy, functional coronary angiography-guided revascularization in STEMI, and transcatheter tricuspid-valve repair in severe tricuspid regurgitation. It summarizes key study findings, clinical implications, and practice-relevant takeaways across prevention, cardiomyopathy, interventional, and structural heart care.
0 Likes
0 Comments
Every decision in antithrombotic therapy carries a delicate balance between preventing thrombosis and minimizing bleeding risk. Join Clot Chronicles, a dedicated forum where healthcare professionals can engage in scientific discussions, gain practical clinical insights, and strengthen evidence-based decision-making to improve patient outcomes.
© 2026 i-rhythm, All Rights Reserved. MSN i-Rhythm does not provide medical advice, diagnosis or treatment.
For unrestricted access to content and a seamless experience,
Complete your profile to help us deliver a more personalized experience.